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The circumsporozoite protein (CSP) of Plasmo-
dium falciparum is a leading candidate antigen
for inclusion in a malaria subunit vaccine. We
describe here the design of a conformationally
constrained synthetic peptide, designated UK-
39, which has structural and antigenic similarity
to the NPNA-repeat region of native CSP. NMR
studies on the antigen support the presence of
helical turn-like structures within consecutive
NPNA motifs in aqueous solution. Intramus-
cular delivery of UK-39 to mice and rabbits on
the surface of reconstituted influenza viro-
somes elicited high titers of sporozoite cross-
reactive antibodies. Influenza virus proteins
were crucially important for the immunostimu-
latory activity of the virosome-based antigen
delivery system, as a liposomal formulation of
UK-39 was not immunogenic. IgG antibodies
elicited by UK-39 inhibited invasion of hepato-
cytes by P. falciparum sporozoites, but not by
antigenically distinct P. yoelii sporozoites. Our
approach to optimized virosome-formulated
synthetic peptide vaccines should be generally
applicable for other infectious and noninfec-
tious diseases.
INTRODUCTION
Malaria is the most important parasitic disease in people
and may cause as many as 2.5 million deaths per annum
[1]. Vaccine development against both Plasmodium falci-
parum and P. vivax is ongoing [2], and one candidateChemistry & Biology 14, 5vaccine, RTS,S/AS02A, demonstrated 30% protection
against the first episode of malaria and 58% protection
against severe malaria in a clinical trial in Mozambican
children [3]. Nevertheless, it is assumed that it will take
at least another decade until a malaria vaccine will be
available that is more effective and more cost effective
than current malaria control tools, such as insecticide-
treated bednets and intermittent preventive treatment in
infants [4–6].
Apart from plans to develop a radiation-attenuated spo-
rozoite vaccine [7], vaccine development against malaria
is focusing largely on subunit vaccine technologies [8]. It
is thought that an effective malaria subunit vaccine will
have to incorporate antigens against several developmen-
tal stages of the parasite. A combination of actions against
sporozoites, infected liver cells, merozoites, and infected
red blood cells may be required to achieve substantial
protective activity [8]. The fact that most vaccines cur-
rently available are based on attenuated or inactivated
whole pathogens or material derived directly from them
demonstrates that the technological problems associated
with peptide and protein subunit vaccine design are still
incompletely solved. Major obstacles include difficulties
in retaining the native conformation of key antibody epi-
topes and the need for an effective but safe human-
compatible exogenous adjuvant in order to achieve
efficient immune responses [9].
We are addressing the problem of protein subunit vac-
cine design by developing synthetic peptide structures
that elicit antibodies against surface epitopes of native
malaria antigens [10–12] and coupling them to the surface
of immunopotentiating reconstituted influenza virosomes
(IRIVs) as a liposomal carrier system [12, 13]. IRIVs are
spherical, unilamellar vesicles, prepared by detergent
removal from a mixture of natural and synthetic phospho-
lipids and influenza surface glycoproteins. The hemagglu-
tinin membrane glycoprotein of the influenza virus is a77–587, May 2007 ª2007 Elsevier Ltd All rights reserved 577
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Discussed in the Textfusion-inducing component, which facilitates antigen de-
livery to immunocompetent cells. IRIVs represent a univer-
sal antigen delivery system for multicomponent subunit
vaccines, as antigens can be either attached to their sur-
face to elicit antibody responses or encapsulated in their
lumen to elicit CD8 T cell responses. They have an excel-
lent safety profile and are already registered for human
use [14].
Sequential rounds of optimization of synthetic peptide
structures, as typically applied in drug research, may
ideally lead to vaccine candidate antigens which elicit
primarily or exclusively antibodies that contribute to im-
mune protection. In the case of the central repeat region
(NPNA)z37 of the circumsporozoite protein (CSP) of P. fal-
ciparum sporozoites, results of clinical trials with a linear
(NANP)3 peptide conjugated to tetanus toxin in alum [15]
were disappointing. We have previously described the
synthesis and immunological properties of template-
bound NPNA peptides, which were superior to their linear578 Chemistry & Biology 14, 577–587, May 2007 ª2007 Elseviecounterparts in eliciting sporozoite-binding antibodies
[12]. Building on NMR and modeling studies, we designed
and synthesized an improved cyclic NPNA-repeat region
peptide (designated BP-65), which has been shown to ef-
ficiently elicit anti-sporozoite antibody responses in mice
[11]. Here we describe functional properties of monoclo-
nal antibodies (mAbs) elicited by BP-65, and the proper-
ties and preclinical profiling of a synthetically more acces-
sible derivative (UK-39). An IRIV-based formulation of this
peptide, designated PEV302, is currently being tested in
human clinical trials.
RESULTS
Sporozoite-Inhibitory Activity of Anti-BP-65 mAbs
Two mAbs (designated EP3 and EP9) specific for the syn-
thetic compound BP-65 (Figure 1) were generated from
spleen cells of influenza-primed mice immunized with
BP-65-loaded IRIVs. Both mAbs bind to P. falciparumr Ltd All rights reserved
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Synthetic Peptide Malaria Vaccine CandidateFigure 2. Hepatocyte Invasion Inhibition
by Anti-BP-65 mAbs
(A) Inhibition of parasite invasion into primary
human hepatocytes by mAb EP3 and mAb
EP9. Shown is the mean percentage of inhibi-
tion compared to a PBS control ± SD for
duplicates.
(B) Competition of invasion inhibition by in-
creasing concentrations of BP-66 peptide
(BP-65 without PE). Inhibitory mAbs were
used at a constant concentration of 20 mg/ml.sporozoites in immunofluorescence assays (IFAs), and
functional inhibitory activity was assessed by performing
in vitro invasion inhibition assays with P. falciparum sporo-
zoites and primary human hepatocytes. At a concentration
of 200 mg/ml, mAb EP3 caused 82% and mAb EP9 100%
invasion inhibition (Figure 2A). The inhibitory activity de-
creased in a dose-dependent manner when increasing
concentrations of BP-66 were added to the antibody-
parasite mixture (Figure 2B), confirming the specificity of
the inhibitory activity of the mAbs.
Design of UK-40 and Its Phosphatidylethanolamine
Conjugate UK-39
In an attempt to minimize the size of the synthetic vaccine
antigen, a derivative of BP-65, called BP-125, without the
C-terminal PNA and N-terminal NPNA portions, was
produced and tested for reactivity with the sporozoite-
inhibitory anti-BP-65 mAbs EP3 and EP9. Only a strongly
diminished reactivity was observed (see Figure S1 in the
Supplemental Data available with this article online), indi-
cating that BP-65 represents the minimal essential struc-
ture.
In BP-65, the folded conformation of the peptide is sta-
bilized by crosslinking an amino group at the b position of
Pro6 to a spatially adjacent side-chain carboxyl of Glu as
a replacement for Ala16 [11]. As limited availability of
orthogonally protected (2S,3R)-3-aminoproline required
for the synthesis of BP-65 represented an obstacle for
upscaling of the synthesis for clinical-grade material, we
synthesized derivatives of BP-65 designated UK-40 and
UK-39 (phosphatidylethanolamine [PE] conjugate of
UK-40), in which this building block is replaced by
(2S,4S)-4-aminoproline (Figure 1). The required orthogo-
nally protected N(a)-Fmoc(2S,4S)-4-(Boc)aminoproline
([2S,4S]-Boc-4-amino-1-Fmoc-pyrrolidine-2-carboxylic
acid) is commercially available.
NMR Studies of UK-40
The solution structure of UK-40 was investigated in water
(90% H2O, 10% D2O [pH 5.0], 293K) by
1H NMR spectros-
copy. The 1H NMR spectrum of UK-40 indicated the exis-
tence of a major and two minor forms in a ratio of 14:3:1
which interconvert slowly on the NMR timescale, caused
by cis-trans isomerism at Asn-Pro peptide bonds. Similar
cis-trans rotamers were found in BP-66 in earlier work [11]
and in linear peptides containing multiple NPNA repeats
[16]. The major form can be assigned the all-trans confor-
mation on the basis of observed nuclear Overhauser effectChemistry & Biology 14,(NOE) connectivities. Resonance overlap prevented an
assignment of the minor forms to specific peptide-bond
rotamers. Chemical-shift assignments for the major ro-
tamer (Table S1) were made using standard 2D NMR
methods [17]. Side-chain proton frequencies in UK-40 ex-
hibited major spectral overlap, although this problem was
not as severe as seen in linear peptides containing multi-
ple tandem NPNA repeats. This is illustrated in Figure S2,
where HN-C(a)H crosspeaks from 2D DQF-COSY spectra
are shown for UK-40 and the peptide Ac-(NPNA)3-NH2.
Notable in the spectrum of UK-40 are the significantly
upfield shifted amide HN resonances of Asn9 and Ala12.
The amide proton chemical-shift temperature coefficients
were measured and are given in Figure S3. Notable are
the low values for both Ala8 and Asn9, suggesting that
both these amide NHs are involved in intramolecular
hydrogen bonding. A low value is also seen for Ala12, but
not for Asn13.
Two-dimensional NOESY spectra of UK-40 showed
dNN (i, i + 1) NOE connectivities between amide protons
of Asni+3, Alai+4, and Asni+5 within each NAN motif, as
shown in Figure S3. The same pattern of NOE interactions
was also found earlier in BP-66 [11]. Furthermore, charac-
teristic medium-range daN (i, i + 2) NOEs were found be-
tween Asn7 and Asn9, Asn9 and Asn11, Pro10 and Ala12,
and Pro14 and Glu16 in UK-40. Weak NOE contacts be-
tween side chains of the first Asn and the Ala of each
NPNA motif are also seen, as predicted in the structure
model of an NPNA motif in a helical turn conformation
(vide infra) (Figure 3A). No other medium-/long-range
NOEs were observed in NOESY spectra.
Using the available short- and medium-range NOE con-
nectivities, average solution structures for UK-40 were
calculated using DYANA. The final ensemble of 20 struc-
tures (see Table S2) is shown in Figure 3B. The backbone
atoms of residues 6–16 enclosed within the macrocyclic
ring can be superimposed with a root-mean-square devi-
ation of 1.6 A˚, whereas the remaining residues at the N and
C termini show much greater conformational diversity.
When each tetrapeptide motif within the macrocycle is
considered, the highest structural similarity both to the
ANPNA crystal structure [18] and to a model helical turn
conformation is seen in the first (N5-A8) and in particular
the central (N9-A12) tetrapeptide motifs (Figure 4), sug-
gesting that helical turns are significantly populated in
this portion of the molecule. Within the third unit N13-E16,
however, the helical turn conformations are adopted
much less frequently, or not at all, in the 20 lowest-energy577–587, May 2007 ª2007 Elsevier Ltd All rights reserved 579
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significantly populated or, as seems more likely, that the
average NMR structures do not represent accurately
these regions of the macrocycle due to the presence of
multiple rapidly interconverting helical and extended
conformations. The low number and weak intensity of
many NOEs are indicative of significant backbone flex-
ibility. Moreover, the occurrence of significant restraint
violations, such as from the Glu16 C(a)H to Asn17 HN
NOE, indicates also the presence of extended (b) chain
forms.
Antigenic Properties
The antigenic properties of virosomally formulated UK-39
were compared to those of BP-65 [11] and two previously
described [12] template-bound peptides (JL-934 and JL-
1036) (see Figure 1). Panels of CSP-repeat region-specific
sporozoite-binding mAbs obtained after immunization of
mice with either NPNA peptides or with P. falciparum spo-
rozoites were tested in ELISA for crossreactivity with first-
to fourth-generation compounds (Table 1). The results
demonstrate that antibodies with a range of different fine
specificities can bind to native CSP on the sporozoite sur-
face. Thus, mAb 1.26, the only sporozoite crossreactive
Figure 3. Structural Analysis of UK-40
(A) An NPNA motif is depicted in a helical turn conformation (see text).
N atoms, dark blue; O atoms, red; C atoms, gray; amide H atoms, light
white; H bonds, pale blue broken line. Here the first Asn has f/c angles
in the b region, and the following Pro, Asn, and Ala in the a region. A
green ribbon traces the backbone.
(B) Superimposition of the final 20 DYANA structures for UK-40. The
backbone only is represented, superimposed using all backbone
atoms from Apro6 to Glu16 (region in blue).580 Chemistry & Biology 14, 577–587, May 2007 ª2007 ElseviemAb elicited by the antigen JL-934 [12], did not bind
to the other peptide antigens, and only three of the four
sporozoite-binding mAbs elicited by the peptide antigen
JL-1036 [12] crossreacted with the antigens BP-65 and
UK-39. The two mAbs elicited by virosomal formulations
of BP-65 both recognized sporozoites and UK-39,
whereas only one mAb (EP9) recognized JL-1036 and
none JL-934. Crossreactivity analysis with a set of 12
CSP-repeat region-specific mAbs raised against P. falci-
parum sporozoites demonstrated that only 2 of these
mAbs crossreacted with JL-934, 5 with JL-1036, and all
12 with BP-65 and UK-39. While crossreactivity of mAbs
Sp4-7H1 and Sp4-1B4 with the antigen BP-65 was only
weak, all 12 anti-sporozoite mAbs crossreacted strongly
with UK-39, indicating that this compound better reflects
the native structure of the CSP-repeat region.
Immunogenicity of Virosomally Formulated UK-39
Already one immunization of influenza-primed BALB/c
mice with UK-39-loaded IRIVs elicited detectable titers
of anti-UK-39 IgG in ELISA (Figure 5A) and sporozoite
crossreactive IgG in IFA (Figure 5B). While a second im-
munization led to a strong titer increase, a third immuniza-
tion had only a moderate further booster effect. In western
blots with a lysate of P. falciparum salivary gland sporozo-
ites, anti-UK-39 IgG stained a characteristic CSP double
band of 50–55 kDa (data not shown).
Comparison of immune responses elicited by a liposo-
mal and an IRIV-based formulation of UK-39 demon-
strated the importance of influenza virus proteins for the
immunopotentiating activity of IRIVs, in the case of UK-39
not containing any known Th epitopes in the BALB/c
model [19] (Figure 5C). The strong immunogenicity of viro-
somally formulated UK-39 is virtually abolished when the
peptide is presented on liposomes, lacking influenza-
derived hemagglutinin and neuraminidase. Also, no para-
site crossreactive IgG was detected in IFA (data not
shown). Already one dose of IRIV-formulated UK-39 eli-
cited high ELISA and IFA IgG titers in influenza-primed
rabbits (Figure S4). Additional immunizations had only
a minor booster effect. IgG from immunized animals
stained the CSP double band in western blots (data not
shown). IgG from sera taken 2 weeks after the third
immunization (see Figure S4) was purified for sporozoite
inhibition assays.
Generation of Sporozoite-Inhibitory Antibodies
by UK-39
Total IgG (final concentration 1 mg/ml) purified from
UK-39-immunized rabbits showed inhibitory activity in
sporozoite in vitro invasion inhibition assays (Figure 6A).
Inhibition decreased in a dose-dependent manner. Con-
trol IgG preparations from rabbits immunized with empty
IRIVs had no inhibitory activity. Sera-inhibiting invasion
of P. falciparum sporozoites did not inhibit invasion of
P. yoelii into murine hepatocytes (data not shown), dem-
onstrating specificity of the inhibitory activity.
Purified IgG from rabbits immunized with UK-39
inhibited parasite gliding motility, as demonstrated byr Ltd All rights reserved
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Synthetic Peptide Malaria Vaccine CandidateFigure 4. Backbone Superimposition of the 20 DYANA Structures of UK-40 with a Helical Turn Conformation and with the ANPNA
Crystal Structure
Shown with a helical turn conformation (red, [A–C]) and with the ANPNA crystal structure (green, [D–F]).
In (A) and (D), only residues 5–8 in UK-40 were used for the superimposition, for (B) and (E), only residues 9–12, and for (C) and (F), only residues 13–16.immunofluorescence analysis of the trails of CSP shed by
P. falciparum sporozoites gliding on glass slides [20]. At
a concentration of 1 mg/ml of total IgG, traces were re-
duced (Figure 6B). Furthermore, CSP was precipitated at
the apical ends of the sporozoites as described [21] and
sporozoites were agglutinated. Serum of rabbits immu-
nized with empty IRIVs had no effect on gliding motility
or on parasite morphology.
DISCUSSION
An important goal here was the design of a conformation-
ally constrained peptidomimetic of the immunodominant
NPNA-repeat region of CSP, which could be delivered to
the immune system on the surface of IRIVs. Linear pep-
tides are generally unsuitable as immunogens, due to their
inherent conformational flexibility. As a result, there are
many different ways that linear peptides can be recog-
nized (by B cell receptors), correlating with the number
of accessible conformational states available to the pep-
tide chain. Only a small subset of these will be relevant
for crossrecognition of the cognate folded protein. A pep-
tide chain restrained into the biologically relevant back-
bone conformation, on the other hand, should be a more
effective immunogen, as it should be recognized preferen-
tially in a conformation that promotes crossreaction with
the folded protein. There is the further advantage that lin-
ear peptides are usually degraded by proteolysis withinChemistry & Biology 14,minutes in biological fluids, which limits the window of
accessibility to B cell receptors.
Our strategy for the design of a multistage multicompo-
nent subunit malaria vaccine is to focus immune re-
sponses onto protection-relevant structural elements of
key parasite proteins. Moreover, synthetic peptides and
proteins with native-like folds can be presented to the
immune system on IRIVs, thereby bypassing many of
the problems associated with the production of stable
recombinant protein-based vaccine formulations. A key
parameter used for selecting vaccine candidates was
the crossreactivity of elicited antibodies with the native
target antigen on the cell surface of the parasite. IRIV for-
mulations of the peptide antigens evaluated here were im-
munogenic in mice and rabbits. The optimized structure,
UK-39, has remarkable structural and antigenic similarity
with the native repeat region of the key sporozoite vaccine
antigen CSP and is suitable for large-scale good
manufacturing practice production.
Key structural information used to guide the design of
UK-39 came from earlier NMR and modeling studies
[11]. Already, NMR studies on linear peptides containing
one or several tandemly linked NPNA motifs suggested
the presence of turn-like structures based on the NPNA
cadence, stabilized by hydrogen bonding, but in rapid
dynamic equilibrium with extended chain forms [16].
Recently, an X-ray crystal structure was reported of
the pentapeptide Ac-ANPNA-NH2, which confirmed that
the NPNA unit adopts a type I b turn conformation in the577–587, May 2007 ª2007 Elsevier Ltd All rights reserved 581
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mab Immunogen
Crossreactivity with
JL-934a JL-1036a BP-66a UK-39a Sporozoitesb
1.26c JL-934d +   ND +
1.7c +  ND ND 
1.15c +  ND ND 
2.1c JL-1036d  + + + +
3.1c  + + + +
3.2c  +   +
3.3c  + + + +
3.4c  + ND ND 
3.5c  + ND ND 
EP3 BP-66d   + + +
EP9  + + + +
Sp4-5F2 Pf sporozoitese (+) + + + +
Sp4-2H1 (+) + + + +
Sp3-E6  + + + +
Sp3-C6  (+) + + +
Sp3-E9  (+) + + +
Sp4-4B6   + + +
Sp4-7C2   + + +
Sp4-7E4   + + +
Sp4-7H1   (+) + +
Sp4-4D7   + + +
Sp3-B4-C12   + + +
Sp4-1B4   (+) + +
(+), weakly crossreactive; ND, not determined.
a ELISA reactivity to the peptides.
b IFA reactivity with P. falciparum sporozoites.
c Described by Moreno et al. [12].
d Mice were immunized with IRIVs loaded with the respective peptide.
e Mice were immunized with P. falciparum sporozoites isolated from A. stephensi salivary glands in Freund’s adjuvant.crystalline state [18]. Nevertheless, a key question re-
mains how individual b turns in a longer (NPNA)n oligomer
might be interconnected to form a repeat structure. In ear-
lier work, we were strongly influenced by the observation
in NOESY spectra of various (NPNA)n-containing cyclic
and linear peptides of strong sequential backbone
NH-NH NOEs between both Asni+2 and Alai+3 as well as
Alai+3 and Asni+4. This led us to consider backbone con-
formations of extended (NPNA)n oligomeric peptides, in
which Proi+1, Asni+2, and Alai+3 are in the a-helical region,
leaving only Asni in the b region of f/c space, a combina-
tion called here a helical turn. A computer model of such
a turn is shown in Figure 3A, where the close approach
of the backbone amide NHs of Asni+2 and Alai+3 as well
as Alai+3 and Asni+4 can be seen. With these f/c angles
for each NPNA motif, and assuming trans peptide bonds,
a crosslinked peptidomimetic was designed using a582 Chemistry & Biology 14, 577–587, May 2007 ª2007 Elsevcomputer model of an extended (NPNA)n-oligomer, as
described earlier [11]. In our first effort, (2S,3R)-3-amino-
proline was used to synthesize the mimetic BP-66 and
its phospholipid conjugate BP-65. Here we have investi-
gated the related peptidomimetics UK-39 and UK-40 (Fig-
ure 1), which use instead the synthetically more accessible
(2S,4S)-4-aminoproline.
NMR studies on UK-40 in aqueous solution provide in-
sights into the preferred backbone conformations of this
mimetic, and confirm a close similarity to those deduced
earlier for BP-66 [11]. As expected, the residues contained
within the macrocyclic ring of UK-40 are more restrained
in their conformation than the NPNA units outside the
macrocycle at the N and C termini (Figure 3B). The Asn5-
Ala8 and Asn9-Ala12 motifs, in particular, appear to popu-
late helical turns, as seen in the average solution struc-
tures calculated using NOE-derived distance restraintsier Ltd All rights reserved
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Synthetic Peptide Malaria Vaccine CandidateFigure 5. Immunogenicity of Virosomal
and Liposomal Formulations of UK-39
in Influenza-Primed Mice
(A) Anti-UK-39 IgG response in ELISA after
immunization with IRIV-formulated UK-39.
Shown are mean ELISA readouts ± SD ob-
tained with serial dilutions of mouse sera taken
preimmune and 2 weeks after the first, second,
and third immunizations. Sera from ten animals
were analyzed at every time point.
(B) Induction of P. falciparum sporozoite cross-
reactive IgG upon immunization with UK-39.
Shown are IFA endpoint titers and geometric
means of ten individual mice. Sera have been
taken preimmune and 2 weeks after the first,
second, and third immunizations.
(C) Anti-UK-39 IgG response in ELISA of
influenza-primed mice immunized with UK-39
presented either on liposomes or on virosomes.
Shown are the means ± SD of five animals
per group. Sera have been taken 2 weeks after
the third immunization.(Figure 4). However, especially the Asn13-Glu16 motif
within the macrocycle appears to be more disordered
and to exist in dynamic equilibrium with extended forms.
It is less clear what role (if any) the observed minor cis-
(Asn-Pro) peptide-bond conformers might play in eliciting
antibodies crossreactive with CSP. Given that a significant
population of the cis form exists at each Asn-Pro peptide
bond, these minor conformers could play a role in anti-
body recognition. It would certainly be interesting to syn-
thesize and study the immunogenicity and antigenicity of
new mimetics having an increased population of cis ter-
tiary amide bonds, and this will be an important focus of
future work.
As far as the antigenic properties are concerned, UK-39
was recognized by all tested CSP-repeat region-specific
mAbs elicited by sporozoite immunization of mice, and
by the majority of sera from human donors living in malaria
endemic regions (data not shown). One major limitation in
using peptide antigens as vaccine components is their
poor immunogenicity. We demonstrate here that presen-
tation of UK-39 on the surface of virus-like particles elicits
a strong parasite crossreactive antibody response both in
mice and in rabbits. The P. falciparum CSP repeats are
nonimmunogenic in BALB/c mice due to the lack of Th
epitopes [19]. However, we were able to induce high titers
of repeat-specific antibodies with virosomal formulations
of UK-39. Influenza antigens on the surface of virosomes
were essential to compensate for the absence of Th
epitopes in the peptide, as a liposomal formulation of
UK-39 was not immunogenic. We have observed better
immune responses with liposomal formulations of PE con-
jugates of larger peptides including Th epitopes, but also in
these cases, IRIV formulations were superior to liposomal
formulations (unpublished results). The contribution to
immunopotentiating activity of virus protein Th epitopes
versus hemagglutinin-mediated endocytosis of the viro-
somes remains to be elucidated. In immunogenicityChemistry & Biology 14,studies with a range of antigens, we have consistently
found that preexisting anti-influenza immunity enhances
the induction of antibodies against the heterologous
Figure 6. Inhibitory Capacity of Anti-UK-39 Antibodies
In vitro sporozoite invasion inhibition by purified rabbit IgG taken
2 weeks after the third immunization with UK-39.
(A) Shown is the mean percentage of inhibition compared to a PBS
control ± SD of three experiments for two animals immunized with
IRIV-formulated UK-39 (D1 and D3) and one control animal immunized
with empty IRIVs (IRIV).
(B) Fluorescence microscopy of CSP trails deposited by P. falciparum
sporozoites upon gliding on a glass slide. Left panel: trails of sporozoites
incubated with purified IgG from a rabbit immunized with empty IRIVs.
Middle panel: reduced trails of sporozoites incubated with purified IgG
from a UK-39-immunized animal. Right panel: agglutination of sporozo-
ites incubated with purified IgG from a rabbit immunized with UK-39.577–587, May 2007 ª2007 Elsevier Ltd All rights reserved 583
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22]. Widespread outbreaks of influenza have been re-
ported for Africa [23], making the virosomal antigen deliv-
ery system very promising for use in malaria endemic
areas of Africa.
While two immunizations were needed to reach high IgG
titers in mice, one immunization was sufficient in rabbits.
The observed lack of antibody boosting by additional im-
munizations may suggest that high titers of anti-influenza
antibodies enhance clearance of the particles and reduce
immunogenicity of the virosomes. However, in a phase 1
clinical trial with UK-39, no negative correlation between
anti-influenza and anti-UK-39 IgG titers was found (un-
published data).
Seroconversion was not only observed in inbred mice
but also in rabbits with diverse immunogenetic back-
grounds. Genetic restriction of the response in humans
may therefore not represent a serious limitation for IRIV-
based peptide vaccines. As previously observed for other
antigens [13, 22], preimmunization of animals with an influ-
enza vaccine improved the titers of antibodies elicited by
the IRIV formulation (data not shown). Possible explana-
tions for this phenomenon are (1) opsonization of IRIVs
with preexisting anti-influenza antibodies, leading to en-
hanced uptake by antigen-presenting cells, and (2) activa-
tion of influenza-specific memory T cells, providing T cell
help to UK-39-specific B cells. The presence of antibodies
against influenza is not a prerequisite for the induction of
a good immune response but optimizes the adjuvant ef-
fect of virosomes [13]. Preliminary immunogenicity data
of a clinical trial with two IRIV-based malaria vaccine com-
ponents (B. Genton, G.P., L. Degen, A. Kammer, N. West-
erfeld, S.L.O., S. Schroller, P. Vounatsou, M.S.M., M.
Tanner, and R.Z., unpublished data), UK-39 and a peptide
loop derived from the P. falciparum apical membrane an-
tigen 1 [10], support the results obtained in experimental
animals and the general concept of delivering peptides as
IRIV-bound PE conjugates to the human immune system.
Antibodies against BP-65 and its easier to synthesize
derivative UK-39 inhibited sporozoite invasion into hepa-
tocytes in vitro. Inhibition with mAbs against BP-65 was
up to 100%, whereas only lower levels of inhibition were
observed with purified IgG from UK-39-immunized rab-
bits. This reduced effect can be explained by the fact
that we used total IgG from immunized animals. Thus,
despite using high concentrations of IgG (1 mg/ml), only
a minor fraction of the antibodies is specific for the
NPNA repeats. Additionally, physiological serum IgG con-
centrations of humans are around 12 mg/ml, pointing
toward an increased inhibitory effect in vivo. Studies
with purified total IgG from human volunteers immunized
in a phase 1 clinical trial with UK-39 indicate that IFA titers
of parasite-binding anti-UK-39 antibodies correlate very
well both with sporozoite invasion and gliding inhibitory
activity (S.L.O., O.S., N. Westerfeld, M. Curcic, A.
Kammer, M.S.M., R.W.S., J.A.R., B. Genton, D.M., R.Z.,
and G.P., unpublished data).
The mechanism of sporozoite invasion inhibition is
not clearly understood. The observed correlation with584 Chemistry & Biology 14, 577–587, May 2007 ª2007 Elseviinhibition of gliding motility suggests interference with
parasite motility, which is necessary to invade the target
cell, as described before [24]. Whether this inhibition is
based on a specific block of the mechanism promoting
movement or just the result of steric hindrance remains
to be elucidated, as the involvement of CSP in the pro-
cess of gliding motility is still controversial [25]. The pro-
tective potential of anti-CSP-repeat antibodies has been
shown in vivo by passive transfer of anti-CSP-repeat
antibodies, which can protect mice from experimental
sporozoite challenge [26]. The mechanism of this protec-
tion is at least in part due to antibody-mediated immobi-
lization of sporozoites in the skin after injection by the
mosquito [27].
It is not likely that antibodies against UK-39 alone would
result in complete protection against malaria. However, in
the context of a multistage vaccine, they may reduce the
number of sporozoites entering liver cells and thus sup-
port immune protection elicited by components directed
against the liver and blood stages of the malaria parasite.
Moreover, it is thought that reduction of the number of
merozoites released from the liver by anti-pre-erythrocytic
vaccination [3] or reduction of the sporozoite inoculum by
the use of insecticide-treated bednets [28] can reduce the
incidence of severe malaria.
The universal IRIV-based antigen delivery platform
described in this report is highly suitable for combining
antigens specific for the different development stages
of the parasite into a multicomponent malaria subunit
vaccine.
SIGNIFICANCE
With increasing global prevalence of malaria and
emerging resistance of P. falciparum to drug treat-
ment, the need for an efficient malaria vaccine is
greater than ever. Although it was shown more than
30 years ago that humanscanbeprotected againstma-
laria by vaccination [29], a safe, effective, and afford-
able vaccine is still many years away [4]. In particular,
the lack of safe and potent adjuvant/delivery systems
and the technical and regulatory problems associated
with recombinant protein production have hampered
vaccine development. We have developed a technol-
ogy platform based on the design of conformationally
constrained synthetic peptides and the IRIV delivery
system, which allows for the rational development of
a malaria vaccine. The parasite-binding capacity of
antibodies elicited by immunization of mice with
virosomally formulated peptides was used as a key
indicator for the optimization of peptide antigens.
The universal IRIV-based antigen delivery platform
is highly suitable for combining antigens specific for
the different development stages of the parasite into
a multicomponent malaria subunit vaccine. As the
IRIV system is already registered for use in humans,
this platform can contribute to the rapid development
of a safe, efficient, and cost-effective malaria vaccine.er Ltd All rights reserved
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Synthesis of Peptides
Synthesis of JL-934, JL-1036, and BP-65 has been described previ-
ously [11, 12, 30]. For UK-40, a linear peptide was first assembled
on Rink amide 4-methylbenzhydrylamine resin (0.73 mM/g; Novabio-
chem, Nottingham, UK) using an Applied Biosystems ABI433A peptide
synthesizer (Applied Biosystems, Foster City, CA), and Fmoc-
protected amino acids (Fmoc-Asn[Mtt]-OH, Fmoc-Pro-OH, Fmoc-
Ala-OH, Fmoc-Glu[tBu]-OH, and Fmoc-[4S,2S]-4-aminoproline[Boc]-
OH) and HBTU/HOBt (4 eq.) for activation. After cleavage of the linear
peptide from the resin with 95% TFA, 2.5% triisopropylsilane, and
2.5% water over 3 hr, the peptide was precipitated using iPr2O and
dried. The linear peptide was then stirred overnight with HATU
(4 eq.) and HOAt (4 eq.) in DMF with 1% v/v iPr2EtN (2 mg/ml peptide).
After drying in vacuo, the peptide was stirred in 20% piperidine in DMF
for 15 min. The solvent was evaporated and the peptide was precipi-
tated using iPr2O, dried in vacuo, and then purified by reverse-phase
HPLC (35% overall yield after HPLC purification; C18 column using
a gradient of MeCN/H2O [+ 0.1% TFA]; 5%–95% MeCN; tR =
11 min). ES-MS m/z: 2276 (M+H)+.
The cyclic peptide (40 mg) was coupled to PE-CO-(CH2)2-COOH
(PE-succinate; 4 eq.) in DMF (5 ml), CH2Cl2 (5 ml), and 1% iPr2EtN us-
ing HATU and HOAt with stirring overnight at room temperature. The
solvent was then removed and the product was purified by reverse-
phase HPLC (C4 column; Vydac 214 TP 1010, 25 cm3 10 mm; Vydac,
Deerfield, IL) using a gradient of 50% ethanol in water to 100% ethanol
(+ 0.1% TFA) over 15 min. UK-39 appears as a broad peak at about
90% ethanol; yield 15 mg (38%). ES-MS m/z: 1427 (M+2H)2+. Alterna-
tively, the cyclic peptide was acetylated with acetic anhydride in
MeOH and NH4HCO3 buffer and UK-40 was purified by reverse-phase
HPLC (C18 column; Vydac) using a gradient of 0%–100% MeCN in
water. ES-MS m/z: 1049 (M+2H)2+.
PE-succinate was prepared by reacting 1-palmitoyl-3-oleylphos-
phatidylethanolamine (400 mg, 0.57 mmol) in CH2Cl2/MeOH (40 ml,
9:1) with succinic anhydride (67 mg, 0.67 mmol) and Et3N (6 eq.). After
3 hr at room temperature, the organic phase was washed, dried, and
evaporated to afford the product as a white powder (450 mg, 96%).
ES-MS m/z: 816.7 (M+H)+.
NMR Studies
For NMR studies, UK-40 was dissolved in 90% H2O/10% D2O (pH 5.0)
at a concentration of ca. 10 mg/ml. One- and two-dimensional 1H NMR
spectra were recorded at 600 MHz (Bruker AV-600 spectrometer;
Bruker, Billerica, MA). Water suppression was by presaturation. The
sequential resonance assignments were based on DQF-COSY,
TOCSY, and NOESY spectra. Distance restraints were obtained from
NOESY spectra with mixing times of 80 and 250 ms. Spectra were col-
lected with 10243 256 complex data points zero-filled prior to Fourier
transformation to 2048 3 1024, and transformed with a cosine-bell
weighting function. Data processing was carried out with XWINNMR
(Bruker) and XEASY [31].
The structure calculations were performed by restrained molecular
dynamics in torsion angle space by applying the simulated annealing
protocol implemented in the program DYANA [32]. Starting from 100
randomized conformations, a bundle of 20 conformations was se-
lected with the lowest DYANA target energy function. The program
MOLMOL [33] was used for structure analysis and visualization of
the molecular models.
Preparation of Peptide-Loaded Virosomes
For the preparation of IRIVs loaded with phosphatidylethanolamine
(PE)-peptide conjugates, a solution of purified Influenza A/Singapore
hemagglutinin (4 mg) in phosphate-buffered saline (PBS) was centri-
fuged for 30 min at 100,000 3 g and the pellet was dissolved in PBS
(1.33 ml) containing 100 mM octaethyleneglycolmonodecylether
(PBS-OEG). Peptide-PE conjugates (4 mg), phosphatidylcholine
(32 mg; Lipoid, Ludwigshafen, Germany), and PE (6 mg) were dis-Chemistry & Biology 14,solved in a total volume of 2.66 ml of PBS-OEG. The phospholipid
and hemagglutinin solutions were mixed and sonicated for 1 min.
This solution was then centrifuged for 1 hr at 100,000 3 g and the su-
pernatant was filtered (0.22 mm) under sterile conditions. Virosomes
were then formed by detergent removal using Bio-Rad SM BioBeads
(Bio-Rad, Glattbrugg, Switzerland). For the standardization of vaccine
formulations, the content of malaria peptide antigens of the virosomes
was quantified using a validated HPLC method. Furthermore, we
verified that the synthetic PE-linked malaria antigens were exclusively
associated with the virosomal fractions.
Mouse Immunogenicity Studies
BALB/c mice were preimmunized intramuscularly with 1 mg of purified
Influenza A/Singapore hemagglutinin in 0.1 ml PBS. At least 3 weeks
later, they were immunized with PE-peptide conjugate-loaded IRIVs
(containing 10 mg PE-peptide) in intervals of at least 2 weeks. Blood
was collected before each immunization and 2 weeks after the final
injection.
Generation of Hybridomas and Production of mAbs
Hybridomas were generated from spleen cells of mice 3 days after
a booster immunization with BP-65-loaded IRIVs using PAI mouse
myeloma cells as a fusion partner. Hybrids were selected in hypoxan-
thine/aminopterin/thymidine medium and cells that secreted anti-BP-
65 mAbs were identified by ELISA. For large-scale mAb production,
hybridoma cell lines were cultured in 175 cm2 flasks and mAbs were
purified by protein A or G affinity chromatography (protein A Sephar-
ose CL4B or HiTrap protein G HP; Amersham Pharmacia, Piscataway,
NJ). Purified mAbs were dialyzed against PBS, aliquoted, and stored
at 80C. Generation of anti-P. falciparum sporozoite mAbs has
been described previously [34].
Rabbit Immunogenicity Studies
Rabbits were preimmunized intramuscularly with 5 mg of purified Influ-
enza A/Singapore hemagglutinin in 0.1 ml PBS. At least 3 weeks later,
they were immunized with peptide-loaded IRIVs (containing 10 mg
PE-peptide) in intervals of at least 2 weeks. Blood was collected before
each immunization and 2 weeks after the final injection. Rabbit IgG was
purified from immune sera (taken 2 weeks after the third immunization)
by protein A affinity chromatography.
ELISA
ELISA analyses with peptide-PE conjugates were performed essen-
tially as described before [10]. Briefly, Polysorp plates (Nunc; Fisher
Scientific, Wohlen, Switzerland) were coated overnight at 4C with
100 ml of a 10 mg/ml solution of UK-39 in PBS (pH 7.2). After three
washings with PBS containing 0.05% Tween 20, wells were blocked
with 5% milk powder in PBS for 30 min at 37C and washed three times
again. Plates were then incubated with serial dilutions of anti-peptide
mouse or rabbit sera or anti-peptide mAbs in PBS containing 0.05%
Tween 20 and 0.5% milk powder for 2 hr at 37C. After washing, plates
were incubated with alkaline phosphatase-conjugated goat anti-
mouse IgG (Fc-specific) antibodies (Sigma, St. Louis, MO) for 1 hr at
37C. After washing again, a phosphatase substrate solution (1 mg/ml
p-nitrophenyl phosphate [Sigma] in a pH 9.8 buffer solution containing
10% [v/v] diethanolamine and 0.02% MgCl2) was added and the
plates were incubated in the dark at room temperature until the color-
imetric reaction had progressed sufficiently. The optical density was
measured at 405 nm on a Titertek Multiscan MCC/340 reader (Labsys-
tems, Helsinki, Finland). For experiments with rabbit sera, horseradish
peroxidase-conjugated goat anti-rabbit IgG heavy- and light-chain an-
tibodies (Bio-Rad Laboratories, Hercules, CA) were used as secondary
antibody. The TMB microwell peroxidase substrate system (KPL, Gai-
thersburg, MD) was used according to the manufacturer’s protocol
and the OD was measured at 650 nm. After stopping the reaction by
addition of 50 ml of 1 N HCl per well, the OD was measured at 450 nm.577–587, May 2007 ª2007 Elsevier Ltd All rights reserved 585
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Air-dried unfixed P. falciparum (strain NF54) salivary gland sporozoites
attached to microscope glass slides were incubated for 15 min at room
temperature with 25 ml blocking solution containing 1% fatty acid-free
bovine serum albumin in PBS. Immunostaining was performed by in-
cubating the wells with 25 ml of an appropriate serum dilution in block-
ing solution in a humid chamber for 1 hr at room temperature. After five
washes with blocking solution, 25 ml of 5 mg/ml cyanine dye (Cy3)-
conjugated affinity-pure F(ab0)2 fragment goat anti-mouse IgG (Fc-
specific) antibodies (Jackson Immuno Research Laboratories, West
Grove, PA) or Cy3-conjugated donkey anti-rabbit IgG heavy- and
light-chain antibodies (Jackson Immuno Research Laboratories), di-
luted in blocking solution containing 0.01 mg/ml Hoechst dye 33256
(Sigma), were added to the wells and incubated for 1 hr at room tem-
perature. Finally, wells were washed five times with PBS, mounted with
mounting solution (90% [v/v] glycerol containing 0.1 M Tris-Cl [pH 8.0]
and 2 mg/ml o-phenylenediamine), and covered with a coverslip.
Antibody binding and DNA staining were assessed by fluorescence
microscopy on a Leitz Dialux 20 fluorescence microscope (Leitz, Wet-
zlar, Germany) and documented with a Leica DC200 digital camera
system (Leica, Wetzlar, Germany).
SDS-PAGE and Immunoblotting
One hundred microliters of an Anopheles stephensi salivary gland ly-
sate containing about 100,000 P. falciparum sporozoites was diluted
with an equal volume of 23 loading buffer (1.7 ml, 0.5 M Tris-HCl
[pH 6.8], 2 ml glycerol, 4.5 ml 10% SDS, 1 ml b-mercaptoethanol,
0.8 ml 0.3% [w/v] bromophenol blue) and heated to 95C for 10 min.
Proteins were separated on a 10% SDS-PAGE mini-gel. Separated
proteins were electrophoretically transferred to a nitrocellulose filter
(Protran nitrocellulose, BA85; Schleicher & Schuell, Bottmingen, Swit-
zerland) by semidry blotting. Blots were blocked with PBS containing
5% milk powder and 0.1% Tween 20 overnight at 4C. The filter was
cut into strips and incubated with appropriate dilutions of immune
sera in blocking buffer for 2 hr at room temperature. Filter strips
were then washed three times for 10 min in blocking buffer and incu-
bated at room temperature for 1 hr with alkaline peroxidase-conju-
gated goat anti-mouse IgG (Fc-specific) antibodies (Sigma) diluted
1:30,000 in blocking buffer or horseradish peroxidase-conjugated
goat anti-rabbit IgG heavy- and light-chain antibodies (Bio-Rad Labo-
ratories) diluted 1:6,000 in blocking buffer. After washing again, blots
were finally developed using enhanced chemiluminescence western
blotting detection (Amersham Biosciences, Buckinghamshire, UK)
reagents to visualize bands.
P. falciparum and P. yoelii In Vitro Invasion Inhibition Assay
Inhibition assays were performed as described before [35, 36]. Briefly,
primary human or mouse hepatocytes were isolated as described [37,
38], and inoculated with P. falciparum (NF54 strain) or P. yoelii (265BY
strain) sporozoites (13 105/Labtek well) obtained from salivary glands
of infected A. stephensi mosquitoes. After 3 hr at 37C, the cultures
were washed, and further incubated in fresh medium for 3 days (P. fal-
ciparum) or 2 days (P. yoelii) before fixation in methanol. Quantification
of exoerythrocytic forms was done by immunofluorescence. To deter-
mine the effects of anti-CSP antibodies on sporozoite infectivity,
sporozoites were incubated with hepatocytes in the presence of in-
creasing concentrations of mAbs or purified polyclonal rabbit IgG
from immunized animals. The percentage of inhibition was determined
in comparison to a PBS control.
Gliding Inhibition
To analyze sporozoite motility, 30,000 sporozoites were deposited on
multispot glass slide wells precoated with anti-P. falciparum CSP
(PfCSP) mAb E9 (100 mg/ml, 1 hr at 37C) and incubated at 37C for
1 hr. The slides were then washed, and the deposited CSP trails
were fixed with 4% paraformaldehyde for 15 min. The trails were
then labeled using the anti-PfCSP mAb E9 conjugated to Alexa Fluor
488 and visualized under a fluorescence microscope.586 Chemistry & Biology 14, 577–587, May 2007 ª2007 ElsevierSupplemental Data
Supplemental Data include four figures and two tables and are avail-
able at http://www.chembiol.com/cgi/content/full/14/5/577/DC1/.
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